Clinical Progress Filtricine is advancing a human version of the TND diet called Tality as a medical food to manage cancer, with a small-scale prostate cancer trial conducted at Stanford, signaling potential for partnerships with research institutions and healthcare providers.

Strategic Spinout Originating from Stanford University School of Medicine, Filtricine leverages academic credibility to pursue translational biotech opportunities; potential sales angles include collaborations with university tech transfer offices, CROs, and grant-funded programs.

Early Revenue Signals Current revenue range of 1–10 million and total funding around 5.3 million indicate a lean, early-stage company with growing demand; opportunity to engage early adopters in oncology and metabolic disease spaces seeking novel dietary medical foods.

Tech & Platform Utilizes cloud and modern web tech (AWS, Webflow, Google Workspace) for scalable operations and digital outreach; potential to offer digital health platforms, data partnerships, or telehealth-enabled programs to clinics and patient communities.

Industry Fit Operating in biotechnology research with a focus on cancer/metabolic diseases; potential sales channels include large life science distributors, medical food retailers, academic medical centers, and pharmaceutical partners exploring diet-based adjunct therapies.